Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 3 institutions in 2 countries.
Tomayo BeridaDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0002-3578-1033
Samuel R McKeeDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Shamba ChatterjeeDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0003-1415-6981
Destinee L ManningDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0001-7825-5896
Wei LiMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 1682 Campus Delivery, Fort Collins, Colorado 80523, United States.
Pankaj PandeyNational Center for Natural Products Research, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0001-9128-8254
Siddharth Kaushal TripathiNational Center for Natural Products Research, University of Mississippi, University, Mississippi 38677, United States.
Yassin MreyoudDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Asya SmirnovDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Robert J DoerksenDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0002-3789-1842
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 1682 Campus Delivery, Fort Collins, Colorado 80523, United States.ORCID 0000-0002-9212-0258
Christian DuchoDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken 66123, Germany.ORCID 0000-0002-0629-9993
Christina L StallingsDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Sudeshna RoyDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0003-0237-4156
University of Mississippi · USColorado State University · USSaarland University · DE
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Tracking Glycosylation State with Fluorinated Glycosides ProbesP20GM130460 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2020 to 2026
$17.9M
Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI WILLETT, KRISTINE L · 2018 to 2022
$5.3M
MmpL3 as a target for novel anti-TB agentsR01AI116525 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2015 to 2024
$5.3M
Target-based chemotherapeutics development against Mycobacterium tuberculosisR21AI142210 · NIAID · UNIVERSITY OF MISSISSIPPI · PI ROY, SUDESHNA · 2019 to 2020
The rise in multidrug resistant tuberculosis cases underscores the urgent need to develop new treatment strategies for tuberculosis. Herein, we report the discovery and synthesis of a new series of compounds containing a 3-thio-1,2,4-triazole moiety that show inhibition of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting · full record | OpenQuestion